Parkinson's Vaccine – Top Experts Unite in European Consortium
An international consortium of top European research teams has received significant EU funding for the development of therapeutic vaccines against Parkinson's Disease (PD) and Multiple System Atrophy (MSA). Led by the Austrian biotech company AFFiRiS AG, the consortium will use a novel tandem strategy to advance the development of two therapeutic vaccine candidates in parallel. They are both unique in the potential for disease modification, something which is sorely missing in PD as well as in MSA. Both candidates target a protein called alpha-synuclein, which plays a key role in the onset and progression of PD and MSA. Additionally, the group attempts to identify biomarkers with diagnostic and prognostic value. Altogether, the consortium exerts medical and scientific key opinion leaders from Germany, France and Austria. The project SYMPATH has been awarded € 6 Mio. from the 7th Framework Program of the EU and will run for 48 months.
A consortium of top European scientists has been awarded € 6 Mio. for advancing the clinical development of two therapeutic vaccines for the treatment of both Parkinson's Disease (PD) and Multiple System Atrophy (MSA). The vaccine candidates (PD01A and PD03A) form part of the development pipeline of the Austrian biotech company AFFIRIS AG that leads the consortium and the clinical development in the field. Based on the company's renowned AFFITOME®-technology, both vaccines target the protein alpha-synuclein (alpha-syn) which plays a key role in the onset and progression of PD and MSA, the latter being an orphan disease with no registered therapy. Both candidates have already demonstrated their disease-modifying potential in various preclinical model systems.
International & Innovative
Acknowledged as the world-leader in the field of alpha-syn-Immunotherapy, AFFiRiS rallied medical experts and basic scientist from eight high-profile European organizations for the successful FP7 project named SYMPATH. These institutions include the Forschungszentrum Jülich in Germany, the INSERM F-CRIN Toulouse and the departments of Neurology at the University Hospitals of Bordeaux and Toulouse from France, as well as the Medical University of Innsbruck's Department of Neurology and PROSENEX from Austria.
The SYMPATH project especially focuses on an outstanding, innovative approach to the clinical testing of the two candidate vaccines. Using a novel tandem strategy, the consortium will concomitantly evaluate the safety and explore the activity of both vaccine candidates in clinical phase I studies for both indications, PD and MSA. In fact, the tandem strategy allows for direct comparison of the two vaccines already at an early stage in clinical development.
Commenting on this innovative approach, Prof. Achim Schneeberger, responsible for clinical development at AFFiRiS and coordinator of SYMPATH, explained: "This clinical testing strategy developed by the SYMPATH consortium sets a new standard for therapeutic vaccines and disease-modifying agents in neurodegenerative diseases such as PD and MSA." Dr. Markus Mandler of AFFiRiS AG adds: "The tandem strategy is in full accordance with AFFiRiS' clinical maturation program. Based on the excellent safety profile of all vaccine candidates, this program allows for a very quick testing of new vaccine candidates in man. We are very excited that top key opinion leaders are working with us on this project."
In addition to its innovative tandem strategy, the SYMPATH consortium aims to identify biomarkers with diagnostic and prognostic value for both, PD and MSA. Furthermore, it will test the viability of using MSA as a clinical reference indication for synucleinopathies, a group of diseases characterized by the aggregation of alpha-synuclein into so called Lewy Bodies. Using MSA as a clinical reference for synucleinopathies could also greatly benefit therapies in general as MSA treatment gives the fastest positive readout for disease modification upon vaccination. "Based on recent research in neurodegenerative diseases, we have chosen to target not only PD, but also MSA with PD01A and PD03A. If successful, this would address an additional and intense unmet clinical need as MSA is an orphan disease with no registered therapy. Our approach might at the same time provide new scientific insights into the common origin of PD and MSA", Prof. Wassilios Meissner of University Hospital Bordeaux and clinical expert in MSA concludes.
AFFITOME® and AFFITOPE® are registered trademarks of AFFiRiS.
About SYMPATH (http://www.sympath-project.eu/)
SYMPATH ("Reach α-synuclein-dependent neurodegeneration: clinical development of therapeutic AFFITOPE vaccines for Parkinson’s disease and multiple system atrophy") is a collaborative project of the Seventh Framework Programme of the European Union, holding Grant Agreement No. HEALTH-F4-2013-60299. SYMPATH aims to advance the clinical development of therapeutic vaccines targeting alpha-synuclein (alpha-Syn)-driven neurodegenerative diseases including Parkinson’s disease (PD) and multiple system atrophy (MSA) where no causal therapy currently exists. The project will run for 48 months. It has received 5.99 million Euros in funding from the European Union. AFFiRiS AG located in Vienna, Austria serves as the coordinator for the projects ambitious research program and is supported by Biolution in project management tasks. Project partners include 5 universities and 3 SMEs:
AFFiRiS AG (Austria) – Prof. Dr. Achim Schneeberger
Biolution GmbH (Austria) – Dr. Iris Grünert
University Hospital Bordeaux (France) – Prof. Wassilios Meissner, MD
INSERM F-CRIN Toulouse (France) – Claire Levy Marchal, MD, MSc
Prosenex Ambulatorium Betriebs-GmbH (Austria) – Dieter VOLC, MD
Medical University Innsbruck, Department of Neurology (Austria) – Prof. Werner Poewe, MD & Prof. Klaus Seppi, MD
Forschungszentrum Jülich GmbH (Germany) – Prof. Dr. Dieter Willbold
University Hospital Toulouse (France) – Prof. Olivier Rascol, MD
About AFFiRiS AG (Status: April 2014)
Based on the company's own patent positions, AFFiRiS develops tailor-made peptide vaccines for Alzheimer's disease, Atherosclerosis, Parkinson's disease, diabetes and several other conditions with urgent requirement for new treatments and attractive market volumes. Alzheimer's is the current lead indication. AFFiRiS currently employs 100 highly-qualified staff at the Campus Vienna Biocenter in Vienna, Austria (www.affiris.com).
About Parkinson's disease
Parkinson's disease is the second most common neurodegenerative disorder among the elderly with approximately 1.2 Mio European patients alone. Currently there is no cure for the disease and existing therapeutic measures are only able to treat its symptoms. Its classical motor symptoms result from the death of dopamine-generating cells in the substantia nigra, a specific region of the midbrain. The disease typically starts with non-motor symptoms, progresses slowly but steadily to a debilitating state.
About Multiple System Atrophy
Multiple system atrophy is a rare, orphan status neurodegenerative disorder. It progresses rapidly leading to death of the affected individual within, on average, 6-9 years. There is currently no cure for the disease. MSA is associated with the degeneration of nerve cells in specific areas of the brain. This causes problems with movement, balance, and autonomic functions of the body. Unlike Parkinson's disease, where symptomatic treatments are well established, there are no drugs approved for the treatment of MSA.
Contact AFFiRiS AG:
Mag. Julia Bock
1030 Vienna, Austria
T +43 / (0)1 / 798 15 75 – 303
Copy Editing & Distribution:
PR&D – Public Relations for Research & Education
1090 Vienna, Austria
T +43 / (0)1 / 505 70 44
This release was published on openPR.
Permanent link to this press release:
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release Parkinson's Vaccine – Top Experts Unite in European Consortium here
News-ID: 286742 • Views: 5285
More Releases from Affiris
AFFiRiS - MIG-FONDS INCREASES INVESTMENT BY EURO 3 MILLION
Vienna, 25 September 2008. The successful progress of several vaccine programmes run by AFFiRiS GmbH has prompted investor MIG AG to increase its investment in the company. It has set up two new funds - MIG 5 and MIG 7 - to give private investors in Germany and Austria the opportunity to invest in this promising biotech company. The company decided to take this step for two reasons. First, to
AFFIRIS IN BIOTECH SPOTLIGHT 2008 - INDEPENDENT ANALYSIS CONFIRMS GLOBAL POTENTI …
Vienna, Austria, 28 April 2008: According to an analysis carried out by Lifescience-online, due to it\'s AFFITOME technology AFFiRiS GmbH could become a major player in the global pharmaceutical industry. After looking at data from a total of 67 European biotech companies, the study picked out the five firms with the most innovative approaches to therapy and most intensive R&D activities for closer analysis. AFFiRiS GmbH came top of this
AFFIRIS DEVELOPS ALZHEIMER'S VACCINE
Vienna, 17. April 2008. The Viennese biotech company Affiris is today taking stock of the progress achieved to date in its clinical Alzheimer's vaccination programme. All the Alzheimer's patients treated so far as part of the toxicological trials have tolerated the treatment extremely well. As a result, Affiris is among the leading international centres in the race to develop the first causal immunotherapy for Alzheimer's disease. Due to the dramatic
Affiris begins clinical testing of Alzheimer's vaccine
Vienna, 19th July 2007. The Alzheimer's vaccine known as Affitope AD01 from Affiris has now entered the clinical phase of its development. All relevant regulatory and statutory approvals have been secured and this innovative treatment is now being tested on humans for the first time. This development means that the 8.5 million-Euro venture capital finance agreement the company concluded with Munich-based MIG-Fonds in April 2006 has reached a key milestone
More Releases for MSA
Protective Shoes Market Is Thriving Worldwide| MSA, Delta Plus, Lakeland
A latest study released by HTF MI on Southeast Asia Protective Shoes Market covering key business segments and wide scope geographies to get deep dive analysed market data. The study is a perfect balance bridging both qualitative and quantitative information of Southeast Asia Protective Shoes market. The study provides historical data (i.e. Volume** & Value) from 2013 to 2018 and forecasted till 2025*. Some are the key & emerging players
Earmuffs Market is Booming Worldwide | 3M, MSA, Honeywell, Moldex-Metric
HTF MI released a new market study on Global Earmuffs Market with 100+ market data Tables, Pie Chat, Graphs & Figures spread through Pages and easy to understand detailed analysis. At present, the market is developing its presence. The Research report presents a complete assessment of the Market and contains a future trend, current growth factors, attentive opinions, facts, and industry validated market data. The research study provides estimates for
Global Gas Alarm Market 2018 - MSA, Emerson, Crowcon, TROLEX
Apex Market Reports, recently published a detailed market research study focused on the “Gas Alarm Market” across the global, regional and country level. The report provides 360° analysis of “Gas Alarm Market” from view of manufacturers, regions, product types and end industries. The research report analyses and provides the historical data along with current performance of the global PP Pipe industry, and estimates the future trend of Gas Alarm on
Global Flame Detectors Market 2018 - Honeywell International, Tyco, MSA
Apex Market Reports, recently published a detailed market research study focused on the “Flame Detectors Market” across the global, regional and country level. The report provides 360° analysis of “Flame Detectors Market” from view of manufacturers, regions, product types and end industries. The research report analyses and provides the historical data along with current performance of the global PP Pipe industry, and estimates the future trend of Flame Detectors on
Gas Detectors Market 2017 - MSA, Honeywell, Analytics Drager, Emerson
Apex Research, recently published a detailed market research study focused on the "Gas Detectors Market" across the global, regional and country level. The report provides 360° analysis of "Gas Detectors Market" from view of manufacturers, regions, product types and end industries. The research report analyses and provides the historical data along with current performance of the global Gas Detectors industry, and estimates the future trend of Gas Detectors market on
Global Electrical Protective Equipments Market 2017 - Honeywell, Lakeland Indust …
The Global Electrical Protective Equipments Market 2017 examines the performance of the Electrical Protective Equipments market, enclosing an in-depth judgment of the Electrical Protective Equipments market state and the competitive landscape globally. This report analyzes the potential of Electrical Protective Equipments market in the present as well as the future prospects from various angles in detail. The Global Electrical Protective Equipments Market 2017 report includes Electrical Protective Equipments industry volume, market